Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Intellia Thera CS
(NQ:
NTLA
)
22.89
+0.16 (+0.68%)
Streaming Delayed Price
Updated: 11:51 AM EDT, Jun 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Intellia Thera CS
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed
February 26, 2024
On Monday, Cathie Wood-led Ark Invest adjusted its portfolio, notably selling shares of cryptocurrency-related companies such as Robinhood Markets Inc (NASDAQ:HOOD) and Coinbase Global Inc (NASDAQ:
Via
Benzinga
Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought
February 20, 2024
These exciting players could deliver explosive growth over time.
Via
The Motley Fool
3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential
February 19, 2024
Biotech stocks, namely those involved with gene editing, have been explosive and could see higher highs with strong catalysts.
Via
InvestorPlace
Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen?
February 17, 2024
Good news may be on the way, but it will be a while before it arrives.
Via
The Motley Fool
3 Gene Editing Stocks With Unprecedented Surge Potential
February 13, 2024
While CRISPR will certainly be exciting to watch, here are some other gene-editing stocks with unprecedented surge potential.
Via
InvestorPlace
Is It Too Late to Buy Intellia Therapeutics Stock?
January 27, 2024
2024 could be an important year for the biotech.
Via
The Motley Fool
Earnings Scheduled For February 22, 2024
February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.
Via
Benzinga
A Preview Of Intellia Therapeutics's Earnings
February 21, 2024
Via
Benzinga
The 3 Most Undervalued Biotech Stocks to Buy in February 2024
February 08, 2024
With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider.
Via
InvestorPlace
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
February 07, 2024
The widely followed growth investor keeps making moves.
Via
The Motley Fool
Not Shy Of Buying The Dip, Cathie Wood's Ark Mops Up Over $11M Worth Of Shares In Tesla — Sells Nvidia Stock
February 05, 2024
Via
Benzinga
A Bull Market Is Here: 2 Top Growth Stocks to Buy Hand Over Fist
February 05, 2024
These biotech innovators have what it takes to soar.
Via
The Motley Fool
Cathie Wood's Ark Invest Snatches Up $4.7M More In Tesla Shares, Invests Equally In This Rocket Company
February 01, 2024
Via
Benzinga
3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential
January 31, 2024
Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics, for example.
Via
InvestorPlace
History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does.
January 30, 2024
Bull markets generally favor growth stocks, so now is a great time to buy quality growth players.
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street
January 27, 2024
Expectations for these stocks are sky-high, but so are the risks.
Via
The Motley Fool
3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024
January 22, 2024
Biotech stocks are some of the most exciting opportunities on the market. Find the right ones with catalysts, and you could make a fortune.
Via
InvestorPlace
Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics
January 21, 2024
Both companies are going to continue doing high-impact science in 2024.
Via
The Motley Fool
The Top Healthcare Stocks to Buy With $100
January 13, 2024
These companies are shaping the healthcare of tomorrow.
Via
The Motley Fool
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics
January 08, 2024
These two are at very different stages of the clinical trials process.
Via
The Motley Fool
4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024
January 08, 2024
Even if Wall Street is wrong about these stocks in the new year, Cathie Wood could still be right about them over the long run.
Via
The Motley Fool
AlloVir Layoffs 2024: What to Know About the Latest ALVR Job Cuts
January 05, 2024
AlloVir layoffs are coming for 95% of the company's employees as a way to reduce costs and preserve cash after failed clinical trials.
Via
InvestorPlace
Topics
Workforce
Exposures
Layoff
Why Is Medical Properties Trust (MPW) Stock Down 31% Today?
January 05, 2024
Medical Properties Trust stock is falling hard on Friday as investors in MPW react to a rent repayment plan with Steward Health Care System.
Via
InvestorPlace
Intellia Therapeutics Layoffs 2024: What to Know About the Latest NTLA Job Cuts
January 05, 2024
Intellia Therapeutics layoffs are in the news on Friday as the biotech company prepares to cut its total workforce by 15% to reduce costs.
Via
InvestorPlace
Topics
Workforce
Exposures
Layoff
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics
December 31, 2023
Curing rare inherited illnesses could be a lucrative business model.
Via
The Motley Fool
5 Beaten-Down Stocks That Could Soar in 2024
December 16, 2023
These players may offer your portfolio a lift as early as next year. But most importantly, they could excel over time.
Via
The Motley Fool
3 Gene-Editing Stocks With the Potential to Mint Millionaires
December 13, 2023
Gene editing stocks are very likely to see a spike in demand over the coming weeks in the wake of FDA approval of CRISPR.
Via
InvestorPlace
Exposures
Product Safety
Could Intellia Therapeutics Become the Next CRISPR Therapeutics?
December 12, 2023
Intellia is approaching the finish line.
Via
The Motley Fool
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
December 04, 2023
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.